Clinical Trial

Study of CD19 CAR-T Therapy for Refractory SLE

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an investigator-initiated trial aimed at assessing the safety and efficacy of PTOC1 cells Injection in the treatment of refractory systemic lupus erythematosus.
Trial Details
NCT Number NCT07403097
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Systemic Lupus Erythematosus
Enrollment 18 participants
Start Date 2026-02
Primary Completion 2028-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-11